LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.

    Kegele Lignani, Letícia / de Vasconcellos Carvalhaes de Oliveira, Raquel / Matos Dos Santos, Eliane / Antonio Bastos Camacho, Luiz / Reis Xavier, Janaína / Regina da Silva E Sá, Gloria / Mendonça Siqueira, Marilda / Marques Vieira da Silva, Andréa / Gil Melgaço, Juliana / Dos Santos Alves, Nathalia / de Lourdes de Sousa Maia, Maria / Caetano Prates Melo, Enirtes

    Vaccine

    2024  Band 42, Heft 8, Seite(n) 2065–2071

    Abstract: Objective: Assess the level of measles vaccine-induced neutralizing antibodies against the D8 genotype and the persistence of humoral and cell-mediated immunity in children who received their first dose of the measles, mumps, and rubella vaccine eight ... ...

    Abstract Objective: Assess the level of measles vaccine-induced neutralizing antibodies against the D8 genotype and the persistence of humoral and cell-mediated immunity in children who received their first dose of the measles, mumps, and rubella vaccine eight years previously.
    Methods: Measles-specific IgG and neutralizing antibodies were determined in serum using ELISA and plaque reduction neutralization test, respectively. Cellular response was evaluated from peripheral blood mononuclear cells (PBMC). IFN-γ-secreting cells, memory B and T cells, and immunological mediators were assayed by ELISpot, flow cytometry, and multiplex liquid microarray assay, respectively.
    Results: Antibody concentrations declined over time; however, the vaccine-induced neutralizing antibodies' effect against D8 and vaccinal genotypes persisted. PBMC stimulated with the vaccine virus exhibited specific IFN- γ-measles-secreting responses in most participants. Participants with high levels of neutralizing antibodies showed a higher proportion of activated B cells compared to participants with low levels of neutralizing antibodies, while proportions of memory CD4+ and CD8+ T cells were similar between these groups. PBMC supernatant cytokine levels showed a significant difference between stimulated and non-stimulated conditions for IL-2, TNF-α, IL-10, and CXCL10.
    Conclusion: Despite the decline in antibody concentrations over time, the participants still demonstrated neutralizing capacity against the measles D8 genotype five to eight years after the second dose of the measles, mumps, and rubella vaccine. Additionally, most of the enrolled children exhibited cell-mediated immunity responses to measles virus stimulation.
    Mesh-Begriff(e) Child ; Humans ; Mumps/prevention & control ; Leukocytes, Mononuclear ; Measles-Mumps-Rubella Vaccine ; Brazil ; Antibodies, Viral ; Measles ; Antibodies, Neutralizing ; Measles Vaccine ; Immunity, Cellular ; Rubella/prevention & control
    Chemische Substanzen Measles-Mumps-Rubella Vaccine ; Antibodies, Viral ; Antibodies, Neutralizing ; Measles Vaccine
    Sprache Englisch
    Erscheinungsdatum 2024-02-26
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2024.02.060
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1930: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.

    Mouta Nunes de Oliveira, Patricia / Mendes-de-Almeida, Daniela P / Bertollo Gomes Porto, Victor / Crespo Cordeiro, Catherine / Vitiello Teixeira, Gabriellen / Saraiva Pedro, Renata / Roberto Gomes Takey, Paulo / Kegele Lignani, Letícia / Reis Xavier, Janaína / Cardoso Doria da Gama, Vitor / Amorim Filho, Luiz / Emoingt Furtado, Bárbara / Santa Maria, André / Dahrug Barros, Tiago / Neves Waite Freitas, Livia / Dos Santos Pereira, Tainá / Lima Abreu, Debora / Bernardes Ramos, Michael / Gabe, Caroline /
    Arnold, Donald / William Smith, James / Nazy, Ishac / Lourdes de Sousa Maia, Maria de

    Vaccine

    2022  Band 40, Heft 33, Seite(n) 4788–4795

    Abstract: Objective: Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory ... ...

    Abstract Objective: Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory characteristics.
    Methodology: Descriptive case series study using Bio-Manguinhos/Fiocruz/AstraZeneca Brazil and National Immunization Program/Ministry of Health (NIP/MoH) data on COVID-19 AEFI surveillance. We obtained patient-level data from pharmacovigilance for AEFI surveillance and used both the NIP/MoH and Bio-Manguinhos/Fiocruz pharmacovigilance databases to create the study database. Thirty-nine cases of suspect VITT were included, 36 after ChAdOx1 nCoV-19, one after BNT162b2 and two after Ad26.COV2.S vaccine. All cases were based on meeting the Brighton Collaboration criteria for VITT. The primary outcomes were clinical and laboratory features, site of thrombosis, and anti-PF4 ELISA, when available.
    Results: Thirty-nine cases met the criteria, 38 of which were classified as level 1 and one as level 3 according to Brighton Collaboration. Most cases had the central nervous system (CNS) as the main site of thrombosis (21/39) and happened after the vaccine first dose (34/39). The median age of the cases was 41 years old (23 to 86 yo). Most of the cases (61.5%) occurred in women. The median interval between vaccination and onset of symptoms was 8 days (0-37 days). The platelet count and D-dimer count had median values of 34,000/µL and 19,235 µg FEU/L, respectively. The ELISA anti-PF4 antibody was positive in 18 samples. The overall mortality rate was 51% and was higher in cases of CNS thrombosis with intracerebral bleeding.
    Conclusion: Our case series shows that Brazilian VITT cases have similar clinical and laboratory profiles as demonstrated in the literature. Brazil has administered more than 300 million doses of COVID-19 vaccines (more than 110 million from ChAdOx1 nCoV-19). VITT seems to be a very rare but serious adverse event following COVID-19 immunization, especially adenoviral vector immunization.
    Mesh-Begriff(e) Ad26COVS1 ; Adult ; BNT162 Vaccine ; Brazil/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; ChAdOx1 nCoV-19 ; Female ; Humans ; Thrombocytopenia/chemically induced ; Thrombocytopenia/epidemiology ; Thrombosis/chemically induced ; Thrombosis/epidemiology ; Vaccination/adverse effects ; Vaccines/adverse effects
    Chemische Substanzen Ad26COVS1 (JT2NS6183B) ; COVID-19 Vaccines ; Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8) ; BNT162 Vaccine (N38TVC63NU)
    Sprache Englisch
    Erscheinungsdatum 2022-06-16
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2022.06.014
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1930: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil

    Mouta Nunes de Oliveira, Patricia / Mendes-de-Almeida, Daniela P. / Bertollo Gomes Porto, Victor / Crespo Cordeiro, Catherine / Vitiello Teixeira, Gabriellen / Saraiva Pedro, Renata / Roberto Gomes Takey, Paulo / Kegele Lignani, Letícia / Reis Xavier, Janaína / Cardoso Doria da Gama, Vitor / Amorim Filho, Luiz / Emoingt Furtado, Bárbara / Santa Maria, André / Dahrug Barros, Tiago / Neves Waite Freitas, Livia / dos Santos Pereira, Tainá / Lima Abreu, Debora / Bernardes Ramos, Michael / Gabe, Caroline /
    Arnold, Donald / William Smith, James / Nazy, Ishac / Lourdes de Sousa Maia, Maria de

    Vaccine. 2022 Aug., v. 40, no. 33 p.4788-4795

    2022  

    Abstract: Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory characteristics. ... ...

    Körperschaft The Brazillian VITT Investigative Collaboration Group
    Abstract Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory characteristics. Descriptive case series study using Bio-Manguinhos/Fiocruz/AstraZeneca Brazil and National Immunization Program/Ministry of Health (NIP/MoH) data on COVID-19 AEFI surveillance. We obtained patient-level data from pharmacovigilance for AEFI surveillance and used both the NIP/MoH and Bio-Manguinhos/Fiocruz pharmacovigilance databases to create the study database. Thirty-nine cases of suspect VITT were included, 36 after ChAdOx1 nCoV-19, one after BNT162b2 and two after Ad26.COV2.S vaccine. All cases were based on meeting the Brighton Collaboration criteria for VITT. The primary outcomes were clinical and laboratory features, site of thrombosis, and anti-PF4 ELISA, when available. Thirty-nine cases met the criteria, 38 of which were classified as level 1 and one as level 3 according to Brighton Collaboration. Most cases had the central nervous system (CNS) as the main site of thrombosis (21/39) and happened after the vaccine first dose (34/39). The median age of the cases was 41 years old (23 to 86 yo). Most of the cases (61.5%) occurred in women. The median interval between vaccination and onset of symptoms was 8 days (0-37 days). The platelet count and D-dimer count had median values of 34,000/µL and 19,235 µg FEU/L, respectively. The ELISA anti-PF4 antibody was positive in 18 samples. The overall mortality rate was 51% and was higher in cases of CNS thrombosis with intracerebral bleeding. Our case series shows that Brazilian VITT cases have similar clinical and laboratory profiles as demonstrated in the literature. Brazil has administered more than 300 million doses of COVID-19 vaccines (more than 110 million from ChAdOx1 nCoV-19). VITT seems to be a very rare but serious adverse event following COVID-19 immunization, especially adenoviral vector immunization.
    Schlagwörter Adenoviridae ; COVID-19 infection ; antibodies ; blood platelet count ; central nervous system ; databases ; monitoring ; mortality ; thrombocytopenia ; thrombosis ; vaccination ; vaccines ; Brazil ; COVID-19 ; Vaccine-induced immune thrombotic thrombocytopenia
    Sprache Englisch
    Erscheinungsverlauf 2022-08
    Umfang p. 4788-4795.
    Erscheinungsort Elsevier Ltd
    Dokumenttyp Artikel ; Online
    Anmerkung Use and reproduction
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2022.06.014
    Datenquelle NAL Katalog (AGRICOLA)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1930: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang